Tensive is rapidly moving its transformational REGENERA™ / SOFTAG™ devices for breast reconstruction to the market with the support of top-tier investors.

Here’s Tensive at a glance

• Developing REGENERA™ / SOFTAG™ bioresorbable implants
• First approvals expected in 2027
  • EU: REGENERA™ for natural breast reconstruction
  • U.S.: SOFTAG™ for tissue marking after lumpectomy
• Clinical data demonstrating exceptional outcomes
  • 15-patient first-in-human clinical trial showed safety and excellent performance in benign tumor resection (high patient & physician satisfaction)
  • Interim data from 94-patient pivotal study in breast cancer show consistent performance with standard of care, final data for CE Mark submission YE 2025
• Proprietary biopolymer scaffold: 5 patents
• €23 million raised to date (incl. €5M grants)
• 34 FTEs; HQ in Milan, Italy

Investors backing Tensive

Tensive is backed by leading private life sciences specialist investors, as well as regional and competitive grants from public funding institutions throughout Italy and the EU.

In January 2025, Tensive announced that it had successfully closed a €14,000,000 Series A financing led by Panakès Partners SGR, with participation from the EIC Fund, along with other institutional and angel investors. Click here for the press release.

Among our other investors are Recomec, an Italian private investment firm with interests in the life sciences sector, the European Innovation Council, and Cassa Depositi e Prestiti (CDP), the Italian National Promotional Institution fostering the development of the country.